TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details

Profile for Sachin Shah, Pharm.D., BCOP, FCCP

Sachin Shah

Sachin Shah, Pharm.D., BCOP, FCCP

  • Associate Dean for Assessment and Accreditation
  • Associate Professor of Pharmacy Practice
  • Advanced Hematology/Oncology Clinical Pharmacist
Office Phone: 214-376-7459 ext 230
Mail Address: 4500 S. Lancaster, Bldg 7, R#119A
Dallas TX 75216


Dr. Sachin Shah is an Associate Professor and practice as a Hematology/Oncology Clinical Pharmacist. He has created and developed clinical oncology pharmacy program at the Dallas VA Medical Center. Later, Dr. Shah established ASHP accredited Hematology/Oncology Specialty Residency program and trained multiple students and residents through his practice. Dr. Shah has been recipient of Lewis S. Smith Pharmacy Practitioner Award and Lou Cuellar Circle of Excellence awards at the TSHP. In addition, he has received HOPA Clinical Practice Award. Dr. Shah has delivered multiple national presentations and served as a faculty on BCOP Preparatory Review Course. He has published multiple review and original research articles and abstracts in reputed pharmacy and medical journals. Further, Dr. Shah has written multiple book chapters including the one for PSAP and Koda-Kimble. Dr. Shah has been recognized as a Fellow of the American College of Clinical Pharmacy (FCCP).

Research Interests


Selected Publications:

  • Shah SR. Blood pressure monitoring in patients receiving bevacizumab. Ann Oncol. 2013;24:1127.
  • Bullock KC, Shah SR, Blaszczyk AT, . Race as a factor for intensification of diabetes medications.. Diabetes Educ. 2013;39:335-43.
  • Shah SR. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension.. Ann Oncol. 2013;24:960-65.
  • Shah SR. Adult Sarcomas. American Society of Health-System Pharmacists, Inc.. 2012;(2012):672-698.
  • Shah SR, Ussery S, Dowell J, Marley E, Liticker J, Arriaga Y, Verma U. An evaluation of the incidence of proteinuria and hypertension in patients receiving shorter infusions of bevacizumab.. J Oncol Pharm Practice. 2012;(18(suppl 1)).